BioCentury

INTRODUCTION

Letter from the Editor

PART 1

Imperative of COVID

PART 2

Addressing disparities

PART 3

Data sharing

PART 4

Master protocols

PART 5

Pandemic preparedness

ARTICLE | Product Development

Biopharmas must address the reality of racial disparities in health outcomes exposed by COVID-19

COVID-19 shows why biopharmas need to build racial equity into their drug development mindset

By C. simone fishburn, editor in chief, and Steve Usdin, Washington Editor
September 8, 2020 11:04 PM GMT

Access This Article